Drug Trial News

RSS

Genentech announces results of trastuzumab emtansine Phase II study on HER2-positive mBC

Genentech, a member of the Roche Group, today announced the results of the Phase II study TDM4450g in people with previously untreated HER2-positive metastatic breast cancer.

26 Sep 2011

Afinitor Phase III study on angiomyolipomas associated with TSC meets primary endpoint

A Phase III study of Afinitor (everolimus) tablets in patients with non-cancerous kidney tumors, or angiomyolipomas, associated with tuberous sclerosis complex (TSC) met its primary endpoint of best overall angiomyolipoma response rate, which includes reduction in kidney tumor size and absence of new tumors.

26 Sep 2011

Combination of Afinitor, exemestane reduces risk of breast cancer progression in women

A pivotal Phase III study shows Afinitor (everolimus) tablets plus exemestane, a hormonal therapy, more than doubled the time women lived without tumor growth (progression-free survival; PFS) and significantly reduced the risk of cancer progression by 57% versus exemestane alone in patients with advanced breast cancer.

26 Sep 2011

Patrys announced PAT-SM6 has efficacy against multiple myeloma in preclinical trials

Patrys Limited has announced that its lead anti-cancer antibody PAT-SM6 has shown significant activity in preclinical studies of multiple myeloma.

26 Sep 2011

Combination of abiraterone acetate, prednisone reduces fatigue in men with prostate cancer

Men with prostate cancer that has spread to other parts of the body and that is resistant to hormone therapy suffer less from fatigue if they are treated with a combination of abiraterone acetate and prednisone, according to results from a phase III clinical trial presented today.

26 Sep 2011

Breast cancer drug combination could stop cancer “in its tracks”

The results of a new study revealed that treatment for women with HER2-positive breast cancer – an aggressive form of the disease which is diagnosed in 10,000 British women each year – slowed the progression of tumors by 40 per cent compared with conventional drugs. Tests on 137 women showed that the new therapy – called T-DM1 – which combines the drug Herceptin with an antibody drug, instead of with standard chemotherapy, appeared to stop the cancer “in its tracks”.

26 Sep 2011

Regeneron announces additional data from aflibercept Phase 3 trial on colorectal cancer

Regeneron Pharmaceuticals, Inc. today announced that additional data from the Phase 3 VELOUR trial will be presented at the 2011 European Multidisciplinary Cancer Congress (EMCC) which will take place from September 23-27 in Stockholm, Sweden.

26 Sep 2011

Combination of chemo and radiotherapy in breast cancer: Trial

Breast cancer patients who are given radiotherapy and chemotherapy at the same time have a lower the risk of their tumors coming back and this should be considered as a new treatment approach across the world, cancer experts said on Sunday.

26 Sep 2011

Drug combo for breast cancer in post-menopausal women shows promise

Combining two drugs in post-menopausal women with a certain type of advanced breast cancer more than doubled the time they lived without their disease getting worse, a new study data showed.

26 Sep 2011

Zometa bone drug trial in post-menopausal women with breast cancer

Results from a latest large-scale clinical trial called Azure found that Novartis AG's bone drug Zometa extended survival in older breast cancer patients but failed to improve disease-free survival among younger women patients.

26 Sep 2011

Embryonic stem cell therapy for incurable Stargardt eye disease

...

26 Sep 2011

The Journal of Pain publishes results from Butrans Transdermal System Phase 3 clinical study

Butrans (Buprenorphine) Transdermal System CIII 20 mcg/hour provided significantly lower "average pain over the last 24 hours" scores compared to Butrans 5 mcg/hour when used in opioid-experienced patients with moderate-to-severe chronic low back pain, according to a pivotal Phase 3 clinical study published in the online, August issue of The Journal of Pain.

26 Sep 2011

First Radium-223 Chloride Phase III study in prostate cancer

Until recently, options for patients with bone metastases from advanced prostate cancer have been very limited. But now the first Phase III study of an alpha-pharmaceutical in these patients has shown that it can prolong survival significantly, according to research reported today (Saturday) at the 2011 European Multidisciplinary Cancer Congress.

26 Sep 2011

Combination of everolimus, exemestane holds promise against post-menopausal breast cancer

Results from a phase III clinical trial have shown that combining two existing cancer drugs to treat post-menopausal women with advanced breast cancer resistant to hormonal therapy significantly improves outcome.

26 Sep 2011

RegeneRx completes RGN-259 Phase 2 trial on dry eye syndrome

RegeneRx Biopharmaceuticals, Inc. today announced that treatment and follow-up have been completed on 69 patients in the Company's Phase 2 clinical trial with RGN-259 for the treatment of dry eye syndrome, five more than the number of evaluable patients contemplated in the trial's protocol.

26 Sep 2011

Letrozole reduces risk of breast cancer recurrences and death in post-menopausal women

Results from the longest-running trial comparing tamoxifen with the aromatase inhibitor letrozole show unequivocally that letrozole has withstood the test of time and continues to prevent breast cancer recurrences and reduce the risk of death in post-menopausal women with hormone receptor-positive early breast cancer.

26 Sep 2011

EMA CHMP adopts positive opinion for DIFICLIR to treat C. difficile infection

Astellas Pharma Europe Ltd. (APEL) and Optimer Pharmaceuticals, Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for DIFICLIR (fidaxomicin) tablets for the treatment of adults suffering with a Clostridium difficile infection (CDI), also known as C. difficile-associated diarrhoea (CDAD).

23 Sep 2011

YM BioSciences total revenue decreases to $1.5 million for fiscal 2011

YM BioSciences Inc., a drug development company advancing a diverse portfolio of promising hematology and cancer-related products, today reported operational and financial results for its 2011 fiscal year, ended June 30, 2011.

23 Sep 2011

Data from Amgen's XGEVA and Vectibix studies to be presented at EMCC 2011

Amgen announced today that data from XGEVA (denosumab) and Vectibix (panitumumab) studies will be presented at the 2011 European Multidisciplinary Cancer Congress, Sept. 23 - 27, 2011, in Stockholm, Sweden.

23 Sep 2011

Helsinn commences Netupitant/Palonosetron Phase III combination study in CINV

Helsinn Group and Eisai Inc. announced today that Helsinn has commenced a multi-centered Phase III clinical study program investigating the Netupitant/Palonosetron (300mg/0.50mg) oral fixed-dose combination for the prevention of chemotherapy-induced nausea and vomiting.

23 Sep 2011

Drug Trial News

Genentech announces results of trastuzumab emtansine Phase II study on HER2-positive mBC

Afinitor Phase III study on angiomyolipomas associated with TSC meets primary endpoint

Combination of Afinitor, exemestane reduces risk of breast cancer progression in women

Patrys announced PAT-SM6 has efficacy against multiple myeloma in preclinical trials

Combination of abiraterone acetate, prednisone reduces fatigue in men with prostate cancer

Breast cancer drug combination could stop cancer “in its tracks”

Regeneron announces additional data from aflibercept Phase 3 trial on colorectal cancer

Combination of chemo and radiotherapy in breast cancer: Trial

Drug combo for breast cancer in post-menopausal women shows promise

Zometa bone drug trial in post-menopausal women with breast cancer

Embryonic stem cell therapy for incurable Stargardt eye disease

The Journal of Pain publishes results from Butrans Transdermal System Phase 3 clinical study

First Radium-223 Chloride Phase III study in prostate cancer

Combination of everolimus, exemestane holds promise against post-menopausal breast cancer

RegeneRx completes RGN-259 Phase 2 trial on dry eye syndrome

Letrozole reduces risk of breast cancer recurrences and death in post-menopausal women

EMA CHMP adopts positive opinion for DIFICLIR to treat C. difficile infection

YM BioSciences total revenue decreases to $1.5 million for fiscal 2011

Data from Amgen's XGEVA and Vectibix studies to be presented at EMCC 2011

Helsinn commences Netupitant/Palonosetron Phase III combination study in CINV

How agentic AI is reshaping laboratory workflows

Fourier 80: bringing benchtop NMR systems to the laboratory

How industrial hygiene flow calibration supports defensible exposure data

Latest News